CAR T-cell Therapy Anitocabtagene Autoleucel Achieves 97% Overall Response Rate in Multiple Myeloma Trial
Toronto, canada – Newly presented data from the iMMagine-1 trial reveals anitocabtagene autoleucel, a CAR T-cell therapy, demonstrates a remarkable 97% overall response rate in patients with relapsed and/or refractory multiple myeloma (RRMM). the findings, unveiled at the 2025 International Myeloma Society Annual Meeting, highlight the potential of this treatment to induce deep and durable responses, significantly improving minimal residual disease (MRD)-negativity rates.
multiple myeloma, a cancer of plasma cells, remains a challenging disease to treat, notably after initial therapies fail. These updated results from the Phase 2 iMMagine-1 study offer renewed hope for patients facing limited treatment options. The high response rate and improved MRD-negativity suggest anitocabtagene autoleucel could substantially alter the treatment landscape for RRMM, possibly leading to longer remission periods and improved quality of life. Further examination and potential regulatory approval are anticipated, paving the way for broader patient access.
The iMMagine-1 trial evaluated anitocabtagene autoleucel in patients with RRMM who had previously received four or more lines of therapy. According to a report in Pharmacy Times on May 14,2025,the therapy yielded a 97% overall response rate.
Data also indicates a ample proportion of patients achieved stringent complete remission, a marker of deep disease control. The American Cancer Society details CAR T-cell therapy as a type of immunotherapy that harnesses the patient’s own immune cells to fight cancer.
Researchers, including Kaur G, Freeman C, Dhakal B, and colleagues, presented the updated results at the annual meeting, underscoring the therapy’s efficacy and safety profile.These findings build upon earlier data and reinforce anitocabtagene autoleucel’s position as a promising treatment option for individuals with RRMM.
